Benzinga Bulls and Bears: Ross, Moderna, Webull
Benzinga Bulls and Bears: Ross, Moderna, Webull
View filing at SEC.gov →20 most recent filings and news items mentioning MRNA. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/MRNA/news?limit=20"
Pull MRNA filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayBenzinga Bulls and Bears: Ross, Moderna, Webull
View filing at SEC.gov →COVID-19 Made Moderna Famous: Cancer Could Define Its Future
View filing at SEC.gov →If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now
View filing at SEC.gov →Bessent's Bond Band-Aid, Bitcoin's Best Week Since 2023: This Week on Wall Street
View filing at SEC.gov →MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week
View filing at SEC.gov →Moderna, Webull, Bitmine Immersion, Strategy and Merck: Why These 5 Stocks Are on Investors' Radars Today
View filing at SEC.gov →Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough
View filing at SEC.gov →Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
View filing at SEC.gov →Dow Gains Over 100 Points: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone
View filing at SEC.gov →Stock Market Today: Dow Jones, S&P 500 Futures Fall as Trump Launches 'Operation Economic Fury' on Iran— BULL, WMT, MRK Stock in Focus
View filing at SEC.gov →Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
View filing at SEC.gov →Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday
View filing at SEC.gov →Why Is Tempus AI Stock Gaining Thursday?
View filing at SEC.gov →Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’
View filing at SEC.gov →Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst
View filing at SEC.gov →Why Iovance Biotherapeutics Stock Hit 52-Week High
View filing at SEC.gov →QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History
View filing at SEC.gov →Merck And Moderna Announce Topline Results From The Phase 3 Interpath-001 Trial Evaluating Adjuvant Treatment With Intismeran Autogene In Combination With KEYTRUDA In Patients With Completely Resected Stage IIB-IV Melanoma; At A Pre-specified Interim Analysis, Intismeran In Combi
View filing at SEC.gov →Merck and Moderna Release Landmark Personalized Cancer Therapy Trial Success, Stocks Soar
View filing at SEC.gov →Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
View filing at SEC.gov →